Anupam Verma

8PUBLICATIONS
44CO-AUTHORS
Medical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Infant and child healthHaematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 22, 2025
Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.

Jason N Berman, Anupam Verma, Shelton Viola

|Feb 12, 2025
Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial.

Nirali N Shah, Eric S Schafer, Yueh-Yun Chi

|Sep 25, 2024
Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial.

Marisol Betensky, Maua Mosha, Cristina Tarango

|Feb 10, 2024
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.

Anupam Verma, Yueh-Yun Chi, Jemily Malvar

|Feb 22, 2023
Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study.

N Gossai, D Bhojwani, E S Schafer

|Feb 03, 2023
Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome.

Nikhil Raghuram, Daisuke Hasegawa, Kentaro Nakashima

Pageof 2

Frequent Collaborators

3 joint publications

Bill H Chang

3 joint publications

Johann K Hitzler

2 joint publications

Nathan Gossai

2 joint publications

Michael J Burke